Fortress Biotech Announces First Patient Dosed in Phase II Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

0
355
Fortress Biotech, Inc. announced that the first patient was dosed in a multicenter, placebo-controlled and randomized Phase II clinical trial to evaluate Triplex, a cytomegalovirus (CMV) vaccine, when administered to human leukocyte antigen matched related stem cell donors to reduce CMV events in patients undergoing HSCT.
[Fortress Biotech, Inc.]
Press Release